United States · Pharmaceuticals startup
United States · Neurelis
Neurelis is a specialty pharmaceutical company providing a highly differentiated approach to target unmet medical needs.
Funding reportedLast round: Series D
What company datasets say Neurelis raised
Funding, as reported
Reported in all$206Min dollars
Rounds9
Last roundSeries D
Last round dateMar 2021
Investors listed5
Founders and team
From Neurelis's own website and the SEC filings it signed: 1 founder, 3 on the team.
Craig C. ChamblissPresident and CEO/Co-FounderNamed on its 2021 Form D
- Chuck DeWildtChief Commercial Officer
- Jenny AlonsoGeneral Counsel and Chief Compliance Officer
- George F. StuartExecutive Officeri
On the board, as filediDavid F. HaleHuaizheng C. PengKevin C. LiPriyanka F. BelawatStephen F. Cartt
On 2 portfolio pages
Investors who name them
Each firm lists Neurelis on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
How it ended, so far
Exit
ExitBuyerPriceWhen
AcquiredBiotie TherapiesundisclosedJun 2013
Pharmaceuticals in United States
Startups like it
AMAG PharmaceuticalsWaltham · founded 1981- PL DevelopmentsWestbury · founded 1988
Remedi SeniorCareBaltimore · founded 1954- Spectrum PharmaceuticalsLake Forest · founded 1987
- moksha8 PharmaceuticalsBerwyn · founded 2007
Amplyx PharmaceuticalsSan Diego · founded 2006- Zosano PharmaFremont · founded 2006
Alexza PharmaceuticalsFremont · founded 2001
Is this your company?
Add your raise, your deck and your story, and put Neurelis in front of investors. Or tell us what we have wrong.